9 October 2025AmericasMuireann Bolger

Gilead blocks HIV drug generics for more than 10 years

The pharma giant extends market exclusivity for a top-selling drug accounting for nearly half of its multi-billion-dollar sales.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Gilead deal staves off generic HIV drugs for another six years

20 February 2025 Market leader settles patent disputes with generic drug makers, blocking the release of versions of two key products | More than 80% of HIV patients in the US use Gilead’s treatments.

Americas

Gilead awarded $30m over counterfeit HIV drug scheme

26 November 2024 Wholesaler ‘bought nearly 17,000 bottles of fake Gilead drugs’ | US government says defendant sentenced in September should pay company for lost profits.

Americas

LSPN Fall: Gilead GC shares top drafting tips

17 October 2024 At LSPN Fall North America, in-house counsel offered guidance on how to nail the perfect patent application. Marisa Woutersen reports.

More features

Bridging Brunel and AI: Why CIPA sees ‘a golden opportunity’

Teva in-house counsel jumps to private practice

Brazil’s patent shake-up: How pharma is handling a new reality

Eli Lilly strikes AI drug discovery deal with US biotech

Why AI drug discovery has an IP problem and what can be done

Blank Rome adds more patent attorneys in ‘strategic expansion’

Simmons & Simmons patent litigator jumps ship

ITC probes on the rise, but gender parity lags behind

Gilead blocks HIV drug generics for more than 10 years

More on this story

Editor's picks

Editor's picks

More features